Business Insider

FDA Approves Supplemental New Drug Application for Myrbetriq® (mirabegron) for Use in Combination with solifenacin succinate for the Treatment of Overactive Bladder Symptoms

TOKYO, May 7, 2018 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") announced today that the U.S. Food and Drug Administration (FDA) has approved ...
Business Insider

Astellas Submits Supplemental New Drug Application for Mirabegron for Use in Combination with solifenacin succinate 5 mg for the Treatment of Overactive Bladder

TOKYO, June 29, 2017 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, "Astellas") announced today the submission of a supplemental New Drug Application (sNDA) to ...
FierceBiotech

FDA Advisory Committee Recommends Approval of Mirabegron - Investigational Overactive Bladder Treatment from Astellas

DEERFIELD, Ill., April 5, 2012 /PRNewswire via COMTEX/ -- Astellas Pharma US, Inc. ("Astellas"), a U.S. subsidiary of Tokyo-based Astellas Pharma Inc. (tokyo:4503), announced today that the ...
Medscape

Can a Drug for Overactive Bladder Disease Prevent Progression to Heart Failure?

Interventions for patients with asymptomatic pre-HF may be important in reducing the incidence of clinically overt HF, including HF with preserved ejection fraction (HFpEF). Mirabegron activates the ...
GEN

Bladder Drug May Raise Risk of Blocked Arteries, Heart Disease, and Stroke

Atherosclerosis. Computer artwork of a narrowed artery, due to a cholesterol plaque. A drug that is commonly used to treat overactive bladder could be putting some patients at increased risk of ...